Cereno Scientific’s abstract on CS1’s innovative Phase II study design accepted at top pulmonary vascular congress PVRI held in June, 2022
Cereno Scientific (XSAT: CRNO B) today announced that an abstract regarding the innovative design of the Phase II study with drug candidate CS1 in pulmonary arterial hypertension (PAH) has been accepted as a poster presentation at the 15th Annual World Congress on Pulmonary Vascular Disease in Athens, Greece, on June 22-26, 2022. The abstract is a collaboration between Cereno, Dr. Raymond Benza, global PAH key opinion leader and principal investigator (PI) for the Phase II study and study collaborator Abbott.The abstract with the title “Investigation of efficacy, safety and optimal dose of